Response Predictors
HCV Response Predictors
Coffee Improves Response to Hepatitis C Treatment
- Details
- Category: HCV Response Predictors
- Published on Tuesday, 21 June 2011 07:11
- Written by Liz Highleyman
Drinking more coffee -- but not tea -- was associated with greater likelihood of response to hepatitis C treatment with pegylated interferon/ribavirin in the HALT-C study. 
Early Menopause Linked to Poor Hepatitis C Treatment Response
- Details
- Category: HCV Response Predictors
- Published on Monday, 20 June 2011 15:51
- Written by Liz Highleyman
Women who enter menopause early have worse liver disease but are less likely to achieve sustained response to interferon-based therapy for chronic hepatitis C.
IL28B Gene Variation Linked to Spontaneous Clearance and Treatment Response in HIV/HCV Coinfected People
- Details
- Category: HCV Treatment
- Published on Friday, 12 March 2010 12:48
- Written by Liz Highleyman
A human genetic variation previously shown to predict hepatitis C prognosis in people with HCV alone may play a similar role in HIV/HCV coinfected individuals, according to a set of studies presented at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) last month in San Francisco. The IL28B non-risk genotype associated with both spontaneous HCV clearance and response to interferon-based hepatitis C treatment was less common among people of African descent, perhaps helping explain disparities in treatment outcomes.
Early Menopause Linked to Poor Hepatitis C Treatment Response
- Details
- Category: HCV Response Predictors
- Published on Tuesday, 29 March 2011 00:26
- Written by Liz Highleyman
Women who enter menopause early have worse liver disease but are less likely to achieve sustained response to interferon-based therapy for chronic hepatitis C.
Older Genotype 3 Chronic Hepatitis C Patients Do Not Respond as Well to Interferon-based Therapy
- Details
- Category: HCV Treatment
- Published on Tuesday, 16 June 2009 13:41
- Written by HIVandHepatitis.com
Older age is associated with a lower likelihood of sustained response to pegylated interferon plus ribavirin in genotype 3 chronic hepatitis C patients, and people 50 years or older may benefit from longer treatment, according to a study presented at the recent Digestive Disease Week annual meeting (DDW 2009) in Chicago.
Web Design and Development by